Related Experiment Video

Updated: May 3, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K

FOXP4-AS1 suppresses papillary thyroid carcinoma progression by binding to Lactate Dehydrogenase A and suppressing

Ning Ma1, Hai-Ying Tian2, Wei Zhao3

  • 1Department of Vascular and Thyroid Surgery, Guizhou Provincial People's Hospital, No 83, Zhongshan East Road, Guiyang 550000, China; Guizhou Medical University, No 9, Beijing Road, Guiyang 550004, China.

Cellular Signalling
|May 1, 2026
PubMed

Insights

FOXP4-AS1 acts as a tumor suppressor in papillary thyroid cancer (PTC), inhibiting cell growth and metastasis. It represses Lactate Dehydrogenase A (LDHA) to reduce aerobic glycolysis, offering potential therapeutic strategies for PTC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Papillary thyroid cancer (PTC) progression involves complex molecular mechanisms.
  • The role of long non-coding RNAs like FOXP4-AS1 in PTC is not fully understood.
  • FOXP4-AS1 is known to have oncogenic roles in other cancers.

Purpose of the Study:

  • To investigate the function of FOXP4-AS1 in papillary thyroid cancer.
  • To elucidate the molecular mechanism by which FOXP4-AS1 regulates PTC progression.
  • To identify potential therapeutic targets related to the FOXP4-AS1/LDHA axis.

Main Methods:

  • In vitro experiments assessing cell proliferation, migration, and invasion.
  • In vivo tumorigenesis assays in nude mice.
  • Analysis of FOXP4-AS1 and Lactate Dehydrogenase A (LDHA) expression and localization.
  • Mechanistic studies involving gene knockdown and inhibition.

Main Results:

  • FOXP4-AS1 overexpression suppressed PTC cell proliferation, migration, and invasion.
  • FOXP4-AS1 knockdown promoted malignant phenotypes and enhanced tumor growth in vivo.
  • FOXP4-AS1 interacts with LDHA, a key enzyme in aerobic glycolysis.
  • FOXP4-AS1 knockdown led to increased LDHA expression, which was partially reversed by LDHA inhibition.

Conclusions:

  • FOXP4-AS1 functions as a tumor suppressor in papillary thyroid cancer.
  • The FOXP4-AS1/LDHA axis regulates aerobic glycolysis in PTC.
  • FOXP4-AS1 represses LDHA expression, attenuating aerobic glycolysis and PTC progression.
  • This study provides insights into PTC mechanisms and identifies potential therapeutic and diagnostic targets.
Keywords:
FOXP4-AS1GlycolysisLactate dehydrogenaseLong noncoding RNAsPapillary thyroid carcinoma

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K